July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Effect of intravitreal ranibizumab on intraretinal hard exudates in eyes with diabetic macular edema
Author Affiliations & Notes
  • Sowmya Srinivas
    Ophthalmology, Doheny Eye Institute, Los angeles, California, United States
  • Muneeswar Gupta Nittala
    Ophthalmology, Doheny Eye Institute, Los angeles, California, United States
  • Julie Gasperini
    Ophthalmology, South Coast Retina Center, Long Beach, California, United States
  • Srinivas R. Sadda
    Ophthalmology, Doheny Eye Institute, Los angeles, California, United States
    Department of Ophthalmology, David Geffen School of Medicine at UCLA, Los angeles, California, United States
  • Footnotes
    Commercial Relationships   Sowmya Srinivas, None; Muneeswar Nittala, None; Julie Gasperini, None; Srinivas Sadda, Allergan (F), Allergan (C), Carl Zeiss Meditec (F), CenterVue (C), Genentech (C), Genentech (F), Heidelberg Engineering (C), Iconic (C), NightstarX (C), Novartis (C), Optos (F), Optos (C), Thrombogenics (C), Topcon (C)
  • Footnotes
    Support  none
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 1938. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Sowmya Srinivas, Muneeswar Gupta Nittala, Julie Gasperini, Srinivas R. Sadda; Effect of intravitreal ranibizumab on intraretinal hard exudates in eyes with diabetic macular edema
      . Invest. Ophthalmol. Vis. Sci. 2018;59(9):1938. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To study the effect of monthly 0.3 mg intravitreal ranibizumab injections on intraretinal hard exudates (HEs) and to correlate HE with macular thickness using spectral domain optical coherence tomography (SD-OCT) images of eyes with diabetic macular edema (DME).

Methods : Twenty-two eyes of 22 subjects with DME were included in this IRB-approved prospective longitudinal study. All subjects underwent SD-OCT imaging on a single instrument (Cirrus OCT) at the South Coast Retinal Center in Long Beach, CA. All eyes were imaged using a 512 x 128 macular cube protocol (6 x 6 mm) centered on the fovea, at baseline and monthly for 12 months. For this study, we used the previously published en face grading technique for HE quantification. The en face OCT image and macular thickness values were obtained using commercial instrument software (Cirrus OCT en face analysis and macular thickness analysis 7.5). The en face slab was positioned between the outer border of the ganglion cell layer (GCL) and the external limiting membrane (ELM). HEs appear as sharply demarcated bright foci in these en face images. HEs were segmented and quantified with computer software (Photoshop version CC; Adobe). The mean HE area and the mean macular thickness at baseline and month 12 were compared using a paired t-test and correlated with Pearson analysis.

Results : The average age of the 22 study participants was 65 (+/-8) years and there were 13 females and 9 males. There was a significant decrease (p = 0.003) in mean HE area from a baseline area of 0.48 (+/-0.45) mm2 to a month 12 area of 0.17 (+/-0.20) mm2. The mean absolute difference in HE area from baseline to month 12 was 0.30 mm2. The mean rate of reduction in HE area was 0.025 mm2 per month. Macular thickness significantly decreased (p<0.001) from baseline (332 µm) to month 12 (288 µm). At baseline, HE area significantly correlated with macular thickness (r= 0.5; p= 0.02). Similarly, decrease in HE area significantly correlated with decrease in macular thickness at month 12 visit (r= 0.46; p= 0.04).

Conclusions : In the eyes with DME, monthly intravitreal ranibizumab injections resulted in significant reduction in intraretinal hard exudates which paralleled reductions in macular thickness. En face OCT quantification of HE may be a useful tool for following the progress of lipid exudate resolution during the treatment of DME.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×